Generation of angiotensin II (Ang II) contributes to the pathogenesis of cardiovascular diseases. Owing to the existence of high levels of Ang II within the kidney, blockade of the intrarenal Ang II levels may be important since long term outcome seems not only to be related to blood pressure per se. This was a prospective, randomized, double-blind, placebo-controlled study, with crossover design. We examined in 13 patients with mild to moderate hypertension the specific systemic and renal blocking properties of two different Ang II receptor blockers during a wide range of Ang II concentrations, 24 h post dose. The effects were evaluated after 4 weeks treatment with candesartan cilexetil (16 mg OD), losartan (50 mg OD) and placebo using clearance techniques. Candesartan reduced the 24 h blood pressure better than losartan (138*/87712/8 vs 145/89712/7 mmHg, *Po0.05 vs losartan) and placebo. Despite the lower blood pressure, candesartan attenuated the Ang IIinduced response on ERPF and RVR markedly better than losartan or placebo. The GFR decreased, as expected, with placebo, but remained stable with candesartan. The present study demonstrates that in hypertensive patients candesartan and to a lesser degree losartan are effective in blocking the systemic and renal effects of Ang II during a wide range of Ang II infusion rates. Interestingly, 24 h post dose, candesartan effectively diminished the change in ERPF as well as GFR. This sustained renal effect of candesartan may be of importance, especially in pathophysiological circumstances in which (high renal levels of) Ang II contributes to cardiovascular damage.
Introduction
In patients with primary hypertension, renal vascular resistance is enhanced and renal vascular blood flow is reduced. Like ACE inhibitors, the Ang II receptor blockers have proven to be clinically useful in lowering blood pressure by reducing total peripheral resistance and improving renal vascular resistance through renal vasodilation. 1, 2 Recently, two studies showed that Ang II blockers have a beneficial effect on long-term outcome in the progression of renal disease in hypertensive and nonhypertensive patients with diabetes. 3, 4 Ang II receptor blockers may protect the kidney from damage and prevent structural changes for several reasons. Much of Ang II is formed locally, since intrarenal Ang II contents are higher than can be explained from the circulating Ang II concentrations. 5, 6 Indeed, much of the Ang II-specific effects on tubular functions may be due to locally synthesized Ang II on luminal Ang II receptors. Paradoxically, when the AT-1 receptor is blocked, Ang II production itself could have protecting effects against hypertension and cardiovascular remodelling. By blocking the AT-1 receptor, Ang II can activate the AT-2 receptor, which mediates beneficial antiproliferative and vasodilatory actions. 7, 8 Candesartan cilexetil (candesartan) and losartan selectively block the AT-1 receptor. Although they are both effective in their antihypertensive action, 9, 10 there have been reports that candesartan has superior efficiacy. This may be due to pharma-cokinetic differences, looking to its binding profile. 11, 12 In addition, theoretically, losartan can compete with its own active metabolite, which may contribute to a difference in potency and duration of action as compared to other Ang II receptor blockers.
The present study was designed to further investigate the effects of candesartan cilexetil, losartan and placebo on systemic and renal haemodynamics in patients with mild to moderate hypertension under baseline conditions on the clearance days and during stimulation with a wide range of exogenous Ang II concentrations. Owing to the existence of high levels of Ang II within the kidney, blockade of intrarenal Ang II levels may be important, especially under (patho)physiological circumstances. Therefore, we investigated the specific blocking properties of the Ang II antagonists, candesartan and losartan, as compared to placebo under a wide range of angiotensin II levels.
Methods

Subjects
Studies were carried out in 13 evaluable patients with mild to moderate essential hypertension (diastolic between 95 and 115 mmHg), ranging in age from 39 to 68 years. Patients with secondary forms of hypertension, diabetes mellitus, cardiovascular diseases, including stroke, cardiac failure, angina pectoris during the last 6 months, impaired renal and hepatic function, and other major diseases were excluded from the study. Medical history, physical examination, routine laboratory investigation and an EKG were assessed. Throughout the study, all patients adhered a diet restricted to 100 mmol sodium and 80 mmol potassium.
The study was performed in the University Medical Center Utrecht and Meander Medical Center Amersfoort, with the approval of the local research ethics committees of each hospital and the written informed consent of each subject. It was carried out according to the Declaration of Helsinki.
Study design
The study had a two-center, randomized, doubleblind, placebo-controlled three way cross-over design with a 3-week placebo run-in period. In the runin period, all previous antihypertensive medication were safely withdrawn. At the end of the run-in period, three sitting blood pressure measurements were taken (automatic oscillometer, Omega 2000, Invivo Research Laboratory Inc.). When the mean sitting DBP was 94oDBP4115 mmHg and there were no exclusion criteria, patients were eligible for randomization.
After the run-in period, patients were randomized to receive for 4 weeks either 16 
Ambulatory blood pressure monitoring
At the end of the run-in period and at the end of every treatment period, ambulatory blood pressure was measured from 0600 to 2300 PM at 20-min intervals and from 2300 to 0600 AM at 30-min intervals. The last study drug dose of the treatment period was taken after application of the ABPM (model 90207 SpaceLabs Inc., Washington, Redmond, USA) to the nondominant arm.
Renal assessments
In each subject, three clearance studies were carried out after 4 weeks of treatment with candesartan, losartan and placebo. Adherence to the diet was monitored by 24 h urine collection on the day before each clearance experiment. All measurements were taken in the morning 24 h after the last drug dose and after 12 h fasting prior to the clearance study. The subjects received an oral water load of 25 ml/kg between 0800 and 0900 h. Additional water, matching urine output, was supplied throughout the clearance study. The clearances were performed in the seated position. An antecubital vein was catheterized bilaterally for separate blood sampling and infusions. At 0930 h, a priming dose of a solution containing 10% inulin, to measure GFR, and 2.5% para-aminohippuric acid (PAH), to measure effective renal plasma flow (ERPF), was given, followed by continuous infusion of this solution throughout the remainder of the study. After at least 1 h equilibration, two 30 min baseline urine collections were obtained by spontaneous voiding. Blood specimens were drawn at the midpoint of each collection period from the contralateral arm. Hereafter, angiotensin II (human angiotensin II, Sigma Tau Ethifarma BV, Clinalpha AG, Switzerland) was dissolved in gelofusine (Braun Medical BV Ltd.) and administered by an infusion period of 30 min in doses of 1, 3, 10 and 30 ng/kg/min. Ang II infusion was discontinued when one or more stop criteria were reached: persisting blood pressure exceeding SBP4220 mmHg or DBP4130 mmHg, heart rate o40/min or 4140/min or any unwanted effect believed to be caused by Ang II administration. Urine collection and midpoint blood sampling continued at 30 min interval throughout the study. Blood pressure and heart rate were recorded at 5 min intervals using an automated oscillometer device (Omega 1400, Invivo Research Laboratory Inc., Tulsa, Oklahoma, USA).
Blood and urine samples were analysed for sodium and potassium (flame photometry), inulin and hipurran. Inulin was hydrolysed to fructose and determined photometrically with indolacetic acid. 13 PAH was determined photometrically by a chromogenic aldehyde method. 14 
Neurohormones
Additional blood samples for determination of plasma renin activity (PRA), plasma aldosteron and plasma angiotensin II were obtained before infusion and measured by radioimmunoassay as described previously.
15,16
Calculations and statistics
Values are given as mean with standard error. Blood pressure values are expressed as means and standard deviation. Clearances were calculated according to the standard formula. The clearance of inulin (C inulin) and PAH (C PAH) were regarded as markers of, respectively, glomerular filtration rate (GFR) and ERPF. The filtration fraction (FF) was calculated as GFR/renal plasma flow (RPF). The renal vascular resistance (RVR) was calculated as MAP/renal bloodflow (RBF), and the RBF as RPF/ (1-haematocrit).
To assess the effects of treatment on the 24 h ABPM, hourly values were averaged. A one-way ANOVA for repeated measures on the area under the curve was performed. Statistical analysis of withinday effects of Ang II infusion and of between-days baseline values was made by one-way ANOVA for repeated measures. In case of missing values (which sometimes occurred at the highest Ang II infusion rate), the last measured value was carried over to the missing value. Statistical analysis of between-days differences in response to Ang II infusion was made by one-way ANOVA for repeated measures on the areas under the curve of responses plotted against logarithmically transformed Ang II infusion rates. When significant differences were present according to the ANOVAs, the studentized Newman-Keuls post hoc test was used to analyse these differences. A P-value p0.05 was considered to be statistically significant.
Results
In all, 13 patients with mild to moderate hypertension (diastolic between 95 and 115 mmHg) completed the whole study. The baseline clinical characteristics of the subjects are given in Table 1 .
Systemic hemodynamics
Candesartan reduced the average 24 h systolic and diastolic ABPM more than losartan or placebo (138/ 87712/8 vs 145/89712/7 vs 152/94713/9 mmHg). Figure 1a shows the differences in ABPM between all groups, measured after 4 weeks of treatment and expressed as hourly means of 24 h SBP and DBP. The hourly means of 24 h SBP were significantly lower in the candesartan-treated group, compared to losartan (Po0.05) or placebo (Po0.01). However, there was no statistical significant difference between losartan and placebo. Compared to placebo, the effect on hourly means of 24 h DBP was significantly lower in the candesartan-(Po0.001) and losartan-(Po0.01) treated group. There was no statistical significant difference between the Ang II receptor blockers.
On the clearance day, Ang II infusion induced a dose-related increase in SBP and DBP in all the treatment groups (Figure 1b) . This increase in BP tended to be better blocked by candesartan as compared to losartan or placebo, although no statistical significant difference could be found between the Ang II receptor blockers. However, it should be mentioned that, because of safety criteria during the clearance study, Ang II infusion was discontinued at the highest dose (30 ng/kg/min) in seven patients of the placebo group, in two patients of the losartan group and in no patients of the candesartan group.
Renal haemodynamics
Renal haemodynamics at baseline and during cumulative infusion dose of Ang II are shown in Table 2 and Figure 2 . At baseline, GFR levels were equal in all treatment groups. As expected, the baseline ERPF was higher and the RVR was lower in the candesartan-and losartan-treated period, compared to placebo, although this was not statistically 
Neurohormones
At the end of every treatment period, hormone plasma levels were measured ( Table 2 ). We noted a significant increase of plasma angiotensin II (p-Ang II) in the candesartan-treated period as compared to losartan and placebo. The change in p-Ang II concentration between losartan and placebo was not significant. In addition, there was a significant increase in PRC between all the treatment groups. The change in plasma aldosterone concentration between the treatment groups did not reach a statistically significant difference.
Discussion
This study is a placebo-controlled study that compares, 24 h post dose, the renal and systemic effects of two different Ang II receptor blockers, during a wide range of exogeneous Ang II concentrations. The main finding of the study is that, in patients with mild to moderate hypertension, the Ang II receptor blocker candesartan cilexetil diminished the renal effects of Ang II on ERPF, RVR, glomerular filtration rate and glomerular capillary pressure better than losartan. Interestingly, candesartan was more effective in reducing the decrease in ERPF during exogenous Ang II infusion, even when the blood pressure was lower as compared to losartan or placebo. Also, during candesartan, no change in GFR was observed as compared to placebo. Both Ang II receptor blockers show a significant systemic haemodynamic effect in 24 h blood pressure reduction. These data could implicate that differences exist between Ang II receptor blockers, not only with respect to blood pressure reduction per se, but also with respect to renal haemodynamic effects. This finding may have important clinical consequences. However, it should be stated that the study was performed with losartan 50 mg, which was the maximum recommended dose at the initiation of the study. Losartan 50 mg does not exhibit a clear dose-related response curve. The plateau in the dose-response curve is reached after 50 mg, with a minimal additional effect at 100 mg for blood pressure reduction. [17] [18] [19] In addition, it should be emphasized that the study was performed 24 h post dose.
Systemic haemodynamics
Our data show a larger decrease in 24 h ABPM during long-term treatment with candesartan as compared to losartan or placebo. A possible mechanism for the difference in blood pressure reduction with candesartan is a difference in receptor blockade. Although the pharmacokinetic properties of candesartan and losartan are comparable, 24 h post dose, the pharmacodynamic effects of these two Ang II antagonists are quite different. 11, 20 Candesartan is an 'insurmountable' blocker of the AT-1 receptor, whereas losartan and its active metabolite (EXP 3174) are a mixed competitive/ insurmountable AT-1 receptor antagonist. 11, 12 In agreement with this finding, differences in AT-1 receptor-mediated increase in plasma levels of renin and Ang II were found.
Renal haemodynamics
Previous studies in hypertensive patients showed that long-term treatment with candesartan compared to placebo positively influences renal haemodynamics. The beneficial effects on renal function have been attributed to maintaining glomerular filtration, increasing renal plasma flow, reducing filtration fraction and renal vascular resistance, despite a reduction in mean arterial pressure. 21, 22 Similar studies have been performed in healthy subjects with losartan 23 and irbesartan 24 during exogenous Ang II infusion. Measurements were carried out at peak levels of the Ang II blockers. Both Ang II antagonists blocked the effects of Ang II on renal haemodynamics. Irbesartan also prevented the changes in glomerular function and capillary pressure induced by Ang II.
Intrarenal Ang II contents are much higher than circulating Ang II concentrations, probably due to locally synthesized Ang II. Indeed, it is postulated that the renal vascular bed is more sensitive than systemic vessels, because of the greater AT-1 receptor density, which suggests an important role for Ang II receptor blockers in protecting the kidney against the negative effects of Ang II. 25 As expected from other studies, candesartan and losartan antagonize the effects of Ang II on RVR and RBF significantly. 21, 23 The blocking effects on RVR and RBF, however, are greater in the candersartantreated period as compared to losartan. Also, we demonstrated that, despite the systemic constrictor actions of Ang II, the glomerular filtration remained stable during candesartan treatment 24 h post dose.
This sustained renal effect of candesartan may be of importance in pathophysiological circumstances in which high levels of Ang II may contribute to renal damage and dysfunction, such as hypertension and congestive heart failure. Blockade of the AT-1 receptor by candesartan may prevent an Ang IIinduced functional fall in ERPF, GFR and diminished capacity to excrete sodium.
In our study, two mechanisms may be responsible for the observed difference in renal haemodynamics during Ang II infusion. Ang II plays an important role in the control of the renal circulation. Through vasoconstriction of the afferent and efferent arterioles, Ang II decreases the cortical renal blood flow and glomerular plasma flow. Under normal physiological conditions, the efferent arteriole is more sensitive to Ang II. 26 However some studies indicate that, especially under pathophysiological circumstances, the afferent arteriole becomes more sensitive for the constrictor actions of Ang II. 27, 28 In addition, AT-2 receptors are found in large preglomerular vessels and in the tubular interstitium. [29] [30] [31] Blockade of the AT-1 receptor leads to higher local levels of Ang II and indirectly to stimulation of AT-2 receptors in the preglomerular vessels. Stimulation of the AT-2 receptor may contribute to a larger effect of vasodilation in the afferent arteriole. Our results, on GFR and FF, may suggest that, under conditions of an activated renin-angiotensin system, candesartan could reverse the negative effect of Ang II on the afferent arteriole. This could be important, especially in pathophysiological circumstances in which long-term activation of Ang II in the kidney can contribute to structural changes. Furthermore, in view of the ERPF results, the pharmacologic and pharmacokinetic differences of candesartan compared to losartan may possibly provide a better blockade of the afferent as well as the efferent arteriole.
Secondly, Ang II diminishes the ultrafiltration coefficient (Kf) via a mesangial cell-dependent mechanism. 32 When there is a difference between Ang II blockers in antagonism of the AT-1 receptors of mesangial cells, this could also contribute to the response on GFR during exogenous Ang II activation. Recently Schmitt et al 24 showed that irbesartan, one of the so-called 'insurmountable' AT-1 receptor antagonists, prevented the effects of Ang II on the glomerular ultrafiltration coefficient and the transcapillary glomerular pressure gradient. To our knowledge, no further studies with different Ang II receptor blockers in humans have been carried out to investigate this possible mechanism.
In conclusion, our data show that the Ang II receptor blockers candesartan cilexetil and, to a lesser degree, losartan are effective in blocking the systemic and renal haemodynamics of Ang II in patients with mild to moderate hypertension. Interestingly, candesartan most effectively decreased the reduction in ERPF and GFR during a wide range of exogenous Ang II levels and exhibited a sustained effect for 24 h. This profound and sustained renal effect of candesartan could be of importance, especially in pathophysiological circumstances in which high levels of Ang II can contribute to cardiovascular damage. Furthermore, treatment with blockers of Ang II, such as in patients with hypertension, may be of clinical importance since long-term clinical outcomes on cardiovascular disease depend not only on lowering blood pressure per se, but also on structural changes in target organs, like the heart, kidney and vasculature.
